{
    "Trade/Device Name(s)": [
        "Randox Liquid CK-MB",
        "Randox CK-MB Calibrator"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K123977",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003158"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGS",
        "JIT"
    ],
    "Summary Letter Date": "November 13, 2013",
    "Summary Letter Received Date": "November 18, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "CK-MB"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RX Daytona",
        "RX Imola",
        "RX series instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoinhibition assay"
    ],
    "Methodologies": [
        "Enzyme activity measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Liquid CK-MB and CK-MB Calibrator for quantitative in vitro determination of CK-MB concentration in serum and plasma using immunoinhibition assay on RX series instruments.",
    "Indications for Use Summary": "For quantitative in vitro determination of CK-MB in serum and plasma to aid diagnosis and treatment of myocardial infarction; calibrator intended for calibration of Randox CK-MB methods on clinical laboratory RX series instruments.",
    "fda_folder": "Clinical Chemistry"
}